THOUGHTS ON CARCINOGENESIS TESTING: THE FDA TODAY

Prevention of human cancer in the future will depend on using the results of epidemiologic and animal studies and strategies to minimize exposure. Changes are occurring in the area of animal testing and research that potentially represent significant steps toward reducing our dependence on the tradi...

Full description

Saved in:
Bibliographic Details
Published in:Drug metabolism reviews 2000-01, Vol.32 (2), p.211-214
Main Author: SCHWETZ, B. A.
Format: Article
Language:English
Subjects:
Animals
Carcinogenicity Tests - methods
Carcinogenicity Tests - trends
Humans
Neoplasms - epidemiology
Neoplasms - prevention & control
Risk Management
United States
United States Food and Drug Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prevention of human cancer in the future will depend on using the results of epidemiologic and animal studies and strategies to minimize exposure. Changes are occurring in the area of animal testing and research that potentially represent significant steps toward reducing our dependence on the traditional 2-year bioassay as our primary tool for identification of chemical carcinogens and management of risk. Efforts to prevent cancer would be enhanced by more attention to describing modes of action so that the development of tumors would not be the only basis for predicting carcinogenic potential. These markers might also serve for early detection of cancer at a stage more amenable to treatment. What carcinogens do we want to detect through animal tests in the future? Whether the goal is to identify weak or potent carcinogens, or both, there will still be a need for 2-year bioassays, but hopefully for confirmatory rather than screening purposes.
ISSN:0360-2532
1097-9883
DOI:10.1081/DMR-100100573